201 related articles for article (PubMed ID: 16609301)
1. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
Zoccali C; Kielstein JT
Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
[TBL] [Abstract][Full Text] [Related]
2. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
Gilinskiĭ MA
Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
Ueda S; Yamagishi S; Kaida Y; Okuda S
Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
[TBL] [Abstract][Full Text] [Related]
4. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
Bode-Böger SM; Scalera F; Kielstein JT; Martens-Lobenhoffer J; Breithardt G; Fobker M; Reinecke H
J Am Soc Nephrol; 2006 Apr; 17(4):1128-34. PubMed ID: 16481412
[TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
Fliser D
Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
[TBL] [Abstract][Full Text] [Related]
6. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?
Böger RH
Curr Opin Clin Nutr Metab Care; 2008 Jan; 11(1):55-61. PubMed ID: 18090660
[TBL] [Abstract][Full Text] [Related]
7. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
[TBL] [Abstract][Full Text] [Related]
8. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
9. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Baylis C
Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
[TBL] [Abstract][Full Text] [Related]
10. The endothelium as a target in renal diseases.
Zoccali C
J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
[TBL] [Abstract][Full Text] [Related]
11. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia.
Lücke T; Tsikas D; Kanzelmeyer N; Vaske B; Das AM
Metabolism; 2006 Dec; 55(12):1599-603. PubMed ID: 17142130
[TBL] [Abstract][Full Text] [Related]
12. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
13. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
[TBL] [Abstract][Full Text] [Related]
14. Role of asymmetrical dimethylarginine in the progression of renal disease.
Raptis V; Kapoulas S; Grekas D
Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674
[TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide deficiency in chronic kidney disease.
Baylis C
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F1-9. PubMed ID: 17928410
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
[TBL] [Abstract][Full Text] [Related]
19. Renal parenchymal disease and hypertension.
Preston RA; Epstein M
Semin Nephrol; 1995 Mar; 15(2):138-51. PubMed ID: 7777724
[TBL] [Abstract][Full Text] [Related]
20. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
Tatematsu S; Wakino S; Kanda T; Homma K; Yoshioka K; Hasegawa K; Sugano N; Kimoto M; Saruta T; Hayashi K
J Am Soc Nephrol; 2007 Mar; 18(3):741-9. PubMed ID: 17267746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
